Novo Nordisk | NVO - Current Assets


Novo Nordisk reported DKK31.89B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
ANI Pharmaceuticals USD 747.08M 6.03M Mar/2026
Aurora Cannabis CAD 397.45M 48.38M Mar/2026
Bausch Health Companies USD 6.52B 544M Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Canopy Growth CAD 529.47M 4.8M Mar/2026
Corcept Therapeutics USD 439.68M 13.64M Jun/2026
Drreddys Laboratories INR 301.98B 298.66B Mar/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
Merck USD 35.02B 8.5B Mar/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Novartis USD 27.35B 744M Jun/2026
Novo Nordisk DKK 208.7B 31.38B Jun/2026
Novo Nordisk DKK 31.89B 145.42B Jun/2026
Pacira USD 615.21M 100.25M Jun/2026
Perrigo USD 2.45B 260.7M Jun/2026
Phibro Animal Health USD 894.07M 31.88M Mar/2026
Prestige Brands USD 496.81M 65.33M Jun/2026
Sanofi EUR 31.52B 1.36B Jun/2026
Supernus Pharmaceuticals USD 723.5M 8.08M Jun/2026
Zoetis USD 6.47B 294M Mar/2026